The cost–effectiveness of rituximab in non-Hodgkin’s lymphoma

References

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun T. Cancer Stats 2007. CA Cancer J. Clin.57, 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML. A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood84, 1361–1392 (1994).
   PubMed Web of Science ®Google Scholar
• Anderson CK, Bates PM, Slaughenhoupt B, Pinkus SF, Schlossman SF, Nadler LM. Expression of human B-cell-associated antigens on leukemias and lymphomas: a model of human B-cell differentiation. Blood63, 1424–1433 (1984).
   PubMed Web of Science ®Google Scholar
• The non-Hodgkin’s lymphoma classification project. A clinical evaluation of the international lymphoma study group classification of non-Hodgkin’s lymphoma.Blood89, 3909–3918 (1997).
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J et al. CHOP Chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med.346(4), 235–242 (2002).
   PubMed Web of Science ®Google Scholar
• Paul JE, Trueman P. ‘Fourth hurdle reviews’, NICE, and database applications. Pharmacoepidemiol. Drug Saf.10(5), 429–438 (2001).
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J. Clin. Oncol.23, 4117–4126 (2005).
   PubMed Web of Science ®Google Scholar
• Knight C, Hind D, Brewer N, Abbott V. Rituximab (MabThera®) for aggressive non-Hodgkin’s lymphoma: systematic review and economic evaluation. Health Technology Assessment (Winchester, England). 8(37), iii, ix–xi, 1–82 (2004).
   Google Scholar
• Best JH, Hornberger J, Proctor SJ, Omnes LF, Jost F. Cost–effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma. Value Health8(4), 462–470 (2005).
   PubMed Web of Science ®Google Scholar
• Groot MT, Lugtenburg PJ, Hornberger J, Huijgens PC, Uyl-de Groot CA. Cost–effectiveness of rituximab (MabThera®) in diffuse larger B-cell lymphoma in the Netherlands. Eur. J. Haematol.74, 194–202 (2005).
   PubMed Web of Science ®Google Scholar
• Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer103, 1644–1651 (2005).
   PubMed Web of Science ®Google Scholar
• Proctor SJ, Mackie M, Dawson A et al. A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin’s disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III). Eur. J. Cancer38, 795–806 (2002).
   PubMed Web of Science ®Google Scholar
• Uyl-de-Groot CA, Hagenbeek A, Verdonck LF, Lowenberg B, Rutten FFH. Cost–effectiveness of AMBT in comparison with CHOP chemotherapy in patients with intermediate and high grade malignant non-Hodgkin’s lymphoma (NHL). Bone Marrow Transplant.16, 463–470 (1995).
   PubMed Web of Science ®Google Scholar
• Jantunen E, Itälä M, Juvonen E et al. Autologous stem cell transplantation in elderly (> 60 years) pateints with non-Hodgkin’s lymphoma: a nation-wide analysis. Bone Marrow Transplant.37, 367–372 (2006).
   PubMed Web of Science ®Google Scholar
• Buadi KF, Micallef IN, Ansell SM et al. Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin’s lymphoma. Bone Marrow Transplant.37, 1017–1022 (2006).
   PubMed Web of Science ®Google Scholar
• NICE. Guidance for manufacturers and sponsors. Technology Appraisals Process Series No. 5. National Institute for Clinical Excellence, London, UK (2001).
   Google Scholar
• [No authors listed]. A predictive model for aggressive non-Hodgkin’s lymphoma. The international non-Hodgkin’s lymphoma prognostic factors project. N. Engl. J. Med.329, 987–994 (1993).
   PubMed Web of Science ®Google Scholar
• Wake B, Hyde C, Bryan S et al. Rituximab as third-line treatment for refractory or recurrent stage III or IV follicular non-Hodgkin’s lymphoma: a systematic review and economic evaluation. Health Technol. Assess6(3), 1–85 (2002).
   Google Scholar
• Sweetenham J, Hieke K, Kerrigan M et al. Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin’s lymphoma in the UK. Br. J. Haematol.106, 47–54 (1999).
   PubMed Web of Science ®Google Scholar
• Foran JM, Gupta RK, Cunningham D et al. A UK multicentre Phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br. J. Haematol.109, 81–88 (2000).
   PubMed Web of Science ®Google Scholar
• Roche. Achieving clinical excellence in the treatment of follicular non-hodgkin’s lymphoma. Submission to NICE, London, UK (2006).
   Google Scholar
• Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood105(4), 1417–1423 (2005).
   PubMed Web of Science ®Google Scholar
• Liverpool Reviews and Implementation Group. Rituximab for the first line treatment of stage III-IV follicular non-Hodgkin’s lymphoma. Evidence Review Group Report for the National Institute for Health and Clinical Excellence, London, UK (2006).
   Google Scholar
• Leppä S, Linna M, Nyman H, Taimela E. Cost–effectiveness of rituximab maintenance treatment versus autologous stem cell transplantation (ASCT) in patients with relapsed follicular lymphoma. Blood (Annual Meeting Abstracts) 108 (2006) (Abstract 3337).
   Web of Science ®Google Scholar
• Van Oers MHJ, Van Glabbeke M, Teodorovic I et al. Chimeric anti-CD20 monoclonal antibody (rituximab; Mabthera®) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: final analysis of a Phase III randomized intergroup clinical trial. Presented at: American Society of Hematology 47th Annual Meeting. Georgia, GA, USA, 10–13 December 2005 (Abstract 353).
   Google Scholar
• Maturi B, Mikhael J, Dunlop W, Tilden D, Wong L. Maintenance therapy with rituximab for follicular lymphoma is cost-effective – a Canadian perspective. Blood (ASH Annual Meeting Abstracts) 108 (2006) (Abstract 343).
   Web of Science ®Google Scholar
• Grigg A, Bashford J, Seymour J et al. Autografting followed by rituximab for chemosensitive mantle cell lymphoma: a pilot study and literature review. Leuk. Lymphoma46(6), 851–860 (2005).
   PubMed Web of Science ®Google Scholar